VEGFR JAK EGFR PDGFR HER2 FLT3 FGFR HIF VDA Bcr-Abl Src ALK Syk FAK

Hot Selling Inhibitors in Angiogenesis

JAK Inhibitor

Ruxolitinib (INCB018424) Ruxolitinib (INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Related Products: Tofacitinib,  AZD1480,  Fedratinib

Src Inhibitor

Dasatinib Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Related Products: Saracatinib ,  PP2,  Bosutinib

Tel: +1-832-582-8158 Fax: +1-832-582-8590 Email: [email protected] Address: 9330 Kirby drive, STE 200, Houston, TX 77054 USA Tel: +49-89-46148500 Fax: +49-89-461485022 Email: [email protected] Address: Karl-Schmid-Str. 14, 81829 Munich, Germany